CEO Conversations L: QIC Teams Up with ITRI to Venture into Overseas Markets: Powerful Collaboration Forges Cross-Domain Biotech Innovation Platform
From right to left are Peter Kurz, Chief Strategy Officer of QIC / Alex Lee, Founder and CEO of QIC / Eric Chuang, General Director of Biomedical Technology and Device Research Laboratories (BDL), ITRI / Dr. Maggie Lu, Deputy General Director, Biomedical Technology and Device Research Laboratories (BDL), ITRI
QIC (Quantum International Corp.) and the Industrial Technology Research Institute (ITRI) have jointly announced the creation of a Cross-Domain Biotech Innovation Platform, aiming to foster mutually beneficial collaboration between leading domestic research entities and unique value-creating institutions. Dr. Eric Chuang, General Director of ITRI's Biomedical Technology and Device Research Laboratories, emphasized today the platform's significance as a grand vision to propel Taiwan's outstanding enterprises and scientific technologies onto the international stage. By leveraging QIC's global capital market connections, the platform is expected to yield substantial results efficiently. Alex Lee, Founder and CEO of QIC, also highlighted QIC's role as a comprehensive expert in international capital markets. Coupled with ITRI's research and development resources and QIC’s insights into international capital trends, the partnership is poised to efficiently navigate the journey from research and development to clinical translation and successful commercialization. Alex added, "For the biotech industry, the era of powerful alliances venturing into overseas markets has arrived!"
Under the collaboration, ITRI will provide research and development, regulatory consultation, prototype testing, field verification, government resource integration, and talent cultivation. QIC, on the other hand, will offer insights from international primary and secondary market investors on domestic biotech and medical investments, screen companies with potential, and provide various consulting services for the full lifecycle of company development, including fundraising, listing, major transactions, and M&A.
Since 2023, ITRI has been dedicated to promoting the establishment of the "Cross-Domain Biotech Innovation Platform," partnering with domestic fundraising institutions to strategically collaborate in the biotech field. With a focus on "people flow, capital flow, information flow, and experience flow," ITRI seeks and guides suitable domestic biotech startups to enhance their research and development capabilities. The infusion of capital momentum helps accelerate the commercialization of biotech startups, aiming to enhance the ecosystem of intelligent healthcare. With the addition of QIC, the second major capital fund after CDIB Capital, it is expected that with the support of these two significant biotech capital funds, the "Cross-Domain Biotech Innovation Platform" will become a key driver of Taiwan's biotech industry ecosystem.
Dr. Eric Chuang stated that ITRI has long been deeply involved in the biotech industry, remaining bullish on the development potential and opportunities of Taiwan's biotech industry. Through the integration of various partners, ITRI aims to create a comprehensive and systematic biotech startup ecosystem. The participation of QIC indicates that global capital markets are gradually recognizing the potential of Taiwan's biotech industry. Furthermore, the Cross-Domain Biotech Innovation Platform continues to create opportunities for technical cooperation and experience exchange through successful entrepreneurs and international giants, accelerating the development and application of biotech startups' products, and gradually consolidating and expanding Taiwan's biotech industry ecosystem, firmly establishing its position in the Taiwan market while laying out global opportunities.
Alex Lee, Founder and CEO of QIC, pointed out that behind the success of Taiwan's industries lies the crucial role of wave-makers. The biotech industry essentially is international, hence, to absorb global capital to assist Taiwan's biotech industry in internationalizing is an inevitable trend. The strategic partnership between QIC and ITRI leverages ITRI's strong research expertise with mature research results, and through QIC's extensive network of international investors, suitable investors can be found to promote Taiwan's excellent companies and technologies to the international capital market, supporting entrepreneurs and startups in riding the wave of the biotech boom. For QIC, establishing a smooth capital flow and communication channel for Taiwan's industry is a top priority, by joining the Cross-Domain Biotech Innovation Platform will make the framework more complete.
Since its establishment, QIC has assisted more than 300 companies, arranged meetings with investors from 500 international institutions, conducted more than 20,000 investor conferences, and assisted unlisted and listed companies in raising NT$150 billion in funds and completing major transactions and mergers and acquisitions.
Peter Kurz, Chief Strategy Officer of QIC, further stated that Taiwan's biotech index has grown by 62% over the past three years, far surpassing the NASDAQ Biotechnology Index (NBI) and the Hang Seng Biotechnology Index. Now, Taiwan's third wave of biotech boom is surging, and the international capital market is eager to comprehensively understand Taiwan's excellent medical quality and innovative technology. ITRI, as a key source of industrial technology, looks forward to more cooperation in the future.
In April of this year, QIC held the "15th QIC Taiwan CEO Week" in Singapore, which received enthusiastic responses from international investors. The event attracted 160 global investors and arranged 470 meetings for 33 Taiwanese companies.
QIC will be holding the "QIC Healthcare Corporate Day" from June 12th to 13th, inviting investors from Hong Kong, Singapore, the United States, and Europe to connect with Taiwanese biotech companies, assisting Taiwan's corporate in increasing exposure to the international capital market.
If you would like to join QIC Healthcare Corporate Day, please contact yvonnehuang@qtumic.com.